Clinical Trial Update: Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating azacitidine in transfusion-dependent patients with low-risk myelodysplastic syndrome or chronic myelomonocytic leukemia has co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome
• Myelomonocytic Leukemia

Drugs mentioned

• VIDAZA (AZACITIDINE)

Snippet

Sponsor: Nordic MDS Group | Conditions: Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia | Phase 2 | Status: COMPLETED